NovoCure Limited (FRA:038)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.57B -7.0% |
| Revenue (ttm) | 584.92M +8.5% |
| Net Income | -150.08M |
| EPS | -1.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 12.89 |
| Previous Close | 12.64 |
| Day's Range | 12.89 - 12.89 |
| 52-Week Range | 8.12 - 16.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim... [Read more]
Financial Performance
In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.
Financial numbers in USD Financial StatementsNews
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...
Novocure price target lowered to $46 from $48 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Novocure (NVCR) to $46 from $48 and keeps a Buy rating on the shares. The firm reduced the company’s…
Novocure says Phase 3 TRIDENT trial did not meet primary endpoint
Novocure (NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields therapy for newly diagnosed glioblastoma at the start of chemora...
Novocure's cancer treatment fails to meet late-stage trial goal
Novocure said on Thursday that its cancer treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study.
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy f...
NovoCure Proxy statement: Proxy filing
NovoCure filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Novocure price target raised to $17 from $13.50 at Wells Fargo
Wells Fargo raised the firm’s price target on Novocure (NVCR) to $17 from $13.50 and keeps an Equal Weight rating on the shares. The firm notes Q1 results were ahead…
Novocure price target raised to $20 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Novocure (NVCR) to $20 from $16 and keeps an Outperform rating on the shares.
Novocure reports Q1 EPS (62c), consensus (51c)
Reports 1Q revenue $174.055M, consensus $167.77M. “This was a very strong start to the year for Novocure (NVCR) and we are pleased with the progress made across our commercial and…
Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M
Consensus $694.68M
NovoCure Earnings Call Transcript: Q1 2026
Double-digit growth in active patients and net revenue marked a strong Q1 2026, driven by the successful U.S. launch of Optune Pax for pancreatic cancer and continued momentum in GBM and international markets. Updated guidance reflects confidence in sustained growth and progress toward profitability.
NovoCure Quarterly report: Q1 2026
NovoCure has published its Q1 2026 quarterly earnings report on April 30, 2026.
NovoCure Earnings release: Q1 2026
NovoCure released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
NovoCure Slides: Q1 2026
NovoCure has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Novocure Reports First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend su...
NovoCure Slides: Corporate presentation
NovoCure has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
NovoCure Proxy statement: Proxy filing
NovoCure filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
NovoCure Proxy statement: Proxy filing
NovoCure filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Novocure price target lowered to $16 from $23 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $16 from $23 and keeps an Outperform rating on the shares as part of the firm’s…
Novocure to Report First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will...
Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint
Novocure (NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields, TTFields, therapy concomitant with atezolizumab, gemcitabine and nab-paclitaxel as a first-li...
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (...
NovoCure Transcript: Leerink Global Healthcare Conference 2026
Leadership is driving a shift toward commercially viable indications, focusing on glioblastoma and pancreatic cancer, with disciplined clinical and commercial strategies. Growth is expected from deeper market penetration, new trial data, and leveraging a multi-indication field force.